Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 12/20 | 0.64 |
| ▸ | NPY1R | P25929 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | AQP1 | P29972 | 2/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | NPY2R | P49146 | 1/20 | 0.64 |
| ▸ | NPY4R | P50391 | 1/20 | 0.64 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | SCN1A | P35498 | 2/20 | 0.54 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.54 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5774740 | 1.00 | NPY5R (0.64) | NPY5RNPY1RALDH1A1AQP1ADRA2A | |
| SCHEMBL14606719 | 1.00 | NPY5R (0.64) | NPY5RNPY1RALDH1A1AQP1ADRA2A | |
| SCHEMBL8898328 | 0.90 | NPY5R (0.62) | NPY5RNPY1RALDH1A1AQP1ADRA2A | |
| SCHEMBL8898918 | 0.85 | NPY5R (0.62) | NPY5RNPY1RALDH1A1AQP1ADRA2A | |
| SCHEMBL13796481 | 0.85 | NPY5R (0.62) | NPY5RNPY1RALDH1A1AQP1ADRA2A | |
| SCHEMBL13543086 | 0.84 | NPY5R (0.61) | NPY5RNPY1RALDH1A1AQP1ADRA2A | |
| SCHEMBL8888802 | 0.83 | NPY5R (0.64) | NPY5RNPY1RALDH1A1AQP1ADRA2A | |
| SCHEMBL4007555 | 0.83 | NPY5R (0.67) | NPY5RNPY1RALDH1A1AQP1ADRA2A | |
| SCHEMBL4390192 | 0.83 | NPY5R (0.67) | NPY5RNPY1RALDH1A1AQP1ADRA2A | |
| SCHEMBL8890600 | 0.83 | NPY5R (0.60) | NPY5RNPY1RALDH1A1AQP1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045524-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2008-02-21 | — | — | US | disclosed |
| EP-1816127-A1 | TRIAZINE DERIVATIVES FOR USE AS SELECTIVE NPY (Y5) ANTAGONISTS | H. Lundbeck A/S (DK) | 2007-08-08 | — | — | EP | disclosed |
| US-7189720-B2 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2007-03-13 | — | — | US | disclosed |
| EP-1054887-B1 | BICYCLIC PYRIDINE AND PYRIMIDINE DERIVATIVES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2006-04-12 | — | — | EP | disclosed |
| US-6989379-B1 | Selective NPY (Y5) antagonists | H. LUNDBICK A/S (DK) | 2006-01-24 | — | — | US | disclosed |
| US-20050176709-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2005-08-11 | — | — | US | disclosed |
| US-20040019050-A1 | Selective NPY (Y5) antagonists (triazines) | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-01-29 | — | — | US | disclosed |
| US-6583154-B1 | Neuropeptide Y antagonist; pyrrolo-(3,2-b)pyridines and pyrrolo-(3,2-d)pyrimidines | AMGEN INC. | 2003-06-24 | — | — | US | disclosed |
| US-6569856-B2 | Treatment of feeding disorders, obesity, bulimia nervosa, sexual/reproductive disorders, depression, epileptic seizure, cardiovascular disorders, sleep disturbances | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-05-27 | — | — | US | disclosed |
| US-20020103201-A1 | Selective NPY (Y5) antagonists (triazines) | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-08-01 | — | — | US | disclosed |
| US-6340683-B1 | NEUROPEPTIDE Y ANTAGONISTS; TREATING EATING DISORDERS, SEXUAL/REPRODUCTIVE DISORDERS, DEPRESSION, EPILEPTIC SEIZURE, HYPERTENSION, CEREBRAL HEMORRHAGE, CONGESTIVE HEART FAILURE, SLEEP DISTURBANCES | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-01-22 | — | — | US | disclosed |
| US-6187777-B1 | PYRROLO(3,2-D)PYRIMIDINE DERIVATIVES; NEUROPEPTIDE Y AND CORTICOTROPIN RELEASING FACTOR MODULATORS; DIETETICS; ANTIDIABETIC, ANTIINFLAMMATORY, AND ANTITUMOR AGENTS | AMGEN INC. | 2001-02-13 | — | — | US | disclosed |
| WO-1997020823-A2 | 2-AMINO QUINAZOLINE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019050-A1 | Selective NPY (Y5) antagonists (triazines) | NPY5R, NPY1R, NPY2R | NPY5R 1/4885NPY1R 2/4885ALDH1A1 4535/4885 |
| US-20080045524-A1 | Selective NPY (Y5) antagonists | NPY5R, NPY1R, NPY2R | NPY5R 1/4885NPY1R 2/4885ALDH1A1 4639/4885 |
| US-20020103201-A1 | Selective NPY (Y5) antagonists (triazines) | NPY5R, NPY1R, NPY2R | NPY5R 1/4885NPY1R 2/4885ALDH1A1 4535/4885 |
| US-20050176709-A1 | Selective NPY (Y5) antagonists | NPY5R, NPY1R, NPY2R | NPY5R 1/4885NPY1R 2/4885ALDH1A1 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.